![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
S Houssami, DM Findlay, CL Brady, TJ Martin, RM Epand, EE Moore, E Murayama, T Tamura, RC Orlowski and PM Sexton
St. Vincent's Institute of Medical Research, Fitzroy, Victoria, Australia.
The basis of the high potency of salmon calcitonin (sCT) in radioligand binding competition and cAMP accumulation studies with cloned calcitonin (CT) receptors from rats, pigs, and humans was examined using two sets of CT analogues, i.e., chimeric sCT/human CT (hCT) analogues and analogues of sCT with differing capacities to form an amphipathic alpha-helix. In competition for 125I-sCT binding the following relative specificities were observed for the chimeric peptides: rat C1a CT receptor, sCT > or = (1-16)hCT/(17-32)sCT (ACT-15) > (1-16)sCT/(17-32)hCT (ACT-27); rat C1b CT receptor, sCT >> ACT-15 > ACT-27; hCT receptor, sCT = ACT-15 > ACT-27; porcine CT receptor, sCT > ACT-27 > ACT-15. In contrast, in ligand-induced cAMP accumulation studies the relative efficacies were as follows: rat C1a CT receptor, sCT = ACT-15 > ACT-27; rat C1b CT receptor, sCT = ACT-15 > ACT-27; hCT receptor, sCT = ACT-15 > or = to ACT-27; porcine CT receptor, sCT = ACT- 15 = ACT-27. The data demonstrate that residues present in the carboxyl- terminal half of sCT are more important for binding competition with the rat C1a, rat C1b, and human CT receptors, whereas residues in the amino-terminal half of sCT are more important for binding competition with the porcine CT receptor. Carboxyl-terminal sCT residues are also important for full potency in adenylate cyclase activation with the rat C1a and rat C1b CT receptors but are less important for activation via the hCT receptor. The disparity in the relative potencies of the peptides in studies of binding competition and cAMP accumulation is suggestive of significant differences in the relative affinities of the peptides for active and inactive conformations of the CT receptor. The use of sCT analogues with varying capacities to form alpha-helices also revealed divergence in the responses of different receptors. This was most apparent for the stimulation of cAMP production by the rat receptor isoforms C1a and C1b. In cells expressing the C1a receptor, the helical analogues sCT and des-Ser2-sCT were equipotent with [Gly8]- des-Leu19-sCT and des-1-amino-[Ala1,7,Gly8]-des-Leu19 sCT, analogues that have reduced or absent helical structure, respectively. In contrast, the nonhelical analogues were 100-1000-fold less potent than sCT and des-Ser2-sCT at the C1b receptor. In general, reduction in the ability of sCT analogues to form helix structures had a greater impact on the potency of the analogues in competition for 125I-sCT binding than in cAMP accumulation.(ABSTRACT TRUNCATED AT 400 WORDS)
This article has been cited by other articles:
|
|
 |
|
  G. Andreotti, B. L. Mendez, P. Amodeo, M. A. C. Morelli, H. Nakamuta, and A. Motta Structural Determinants of Salmon Calcitonin Bioactivity: THE ROLE OF THE LEU-BASED AMPHIPATHIC {alpha}-HELIX J. Biol. Chem., August 25, 2006; 281(34): 24193 - 24203. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Thomas, S. Chigurupati, M. Anbalagan, and G. Shah Calcitonin Increases Tumorigenicity of Prostate Cancer Cells: Evidence for the Role of Protein Kinase A and Urokinase-Type Plasminogen Receptor Mol. Endocrinol., August 1, 2006; 20(8): 1894 - 1911. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. J. Rashid, B. F. O'Dowd, and S. R. George Minireview: Diversity and Complexity of Signaling through Peptidergic G Protein-Coupled Receptors Endocrinology, June 1, 2004; 145(6): 2645 - 2652. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Pham, J. D. Wade, B. W. Purdue, and P. M. Sexton Spatial Proximity between a Photolabile Residue in Position 19 of Salmon Calcitonin and the Amino Terminus of the Human Calcitonin Receptor J. Biol. Chem., February 20, 2004; 279(8): 6720 - 6729. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Seck, R. Baron, and W. C. Horne The Alternatively Spliced {Delta}e13 Transcript of the Rabbit Calcitonin Receptor Dimerizes with the C1a Isoform and Inhibits Its Surface Expression J. Biol. Chem., June 13, 2003; 278(25): 23085 - 23093. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. R. Poyner, P. M. Sexton, I. Marshall, D. M. Smith, R. Quirion, W. Born, R. Muff, J. A. Fischer, and S. M. Foord International Union of Pharmacology. XXXII. The Mammalian Calcitonin Gene-Related Peptides, Adrenomedullin, Amylin, and Calcitonin Receptors Pharmacol. Rev., June 1, 2002; 54(2): 233 - 246. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Evdokiou, L.-J. Raggatt, G. J. Atkins, and D. M. Findlay Calcitonin Receptor-Mediated Growth Suppression of HEK-293 Cells Is Accompanied by Induction of p21WAF1/CIP1 and G2/M Arrest Mol. Endocrinol., October 1, 1999; 13(10): 1738 - 1750. [Abstract] [Full Text]
|
|
|
|
 |
|
 G. Christopoulos, K. J. Perry, M. Morfis, N. Tilakaratne, Y. Gao, N. J. Fraser, M. J. Main, S. M. Foord, and P. M. Sexton Multiple Amylin Receptors Arise from Receptor Activity-Modifying Protein Interaction with the Calcitonin Receptor Gene Product Mol. Pharmacol., July 1, 1999; 56(1): 235 - 242. [Abstract] [Full Text]
|
|
|
|
|
|
G. Pozvek, J. M. Hilton, M. Quiza, S. Houssami, and P. M. Sexton Structure/Function Relationships of Calcitonin Analogues as Agonists, Antagonists, or Inverse Agonists in a Constitutively Activated Receptor Cell System Mol. Pharmacol., April 1, 1997; 51(4): 658 - 665. [Abstract] [Full Text]
|
|
|
|
|
|
L. J. Deftos, MD Editorial: There's Something Fishy and Perhaps Even Fowl about the Mammalian Calcitonin Receptor and Its Ligand Endocrinology, February 1, 1997; 138(2): 519 - 520. [Full Text] [PDF]
|
|
|
|
|
|
M. Quiza, M. Dowton, K. J. Perry, and P. M. Sexton Electrophoretic Mobility and Glycosylation Characteristics of Heterogeneously Expressed Calcitonin Receptors Endocrinology, February 1, 1997; 138(2): 530 - 539. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Bergwitz, T. J. Gardella, M. R. Flannery, J. T. Potts Jr., H. M. Kronenberg, S. R. Goldring, and H. Juppner Full Activation of Chimeric Receptors by Hybrids between Parathyroid Hormone and Calcitonin. EVIDENCE FOR A COMMON PATTERN OF LIGAND-RECEPTOR INTERACTION J. Biol. Chem., October 25, 1996; 271(43): 26469 - 26472. [Abstract] [Full Text] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
